← Barinthus Biotherapeutics plc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4.8m |
$268k
-94.44%
|
$44.7m
+16580.22%
|
$1.9m
-95.79%
|
$15.1m
+701.70%
|
$16k
-99.89%
|
$0
-100.00%
|
|
| Net Interest Income | — | — | $3.1m |
$2.8m
-7.62%
|
$2.6m
-7.86%
|
$1.9m
-27.39%
|
$1.5m
-20.36%
|
|
| Research and development | $14.4m | $20.4m | $42.4m | $44.9m | $42.2m | $25.6m | $16.3m | |
| Research and development incentives | $3.3m | $4.0m | $1.2m | $3.5m | $4.0m | $2.0m | $16.3m | |
| General and administrative | $10.5m | $25.1m | $6.4m | $39.8m | $29.7m | $40.8m | $22.4m | |
| Amortization of Intangible Assets | $0 | $182k | $3.2m | $3.2m | $3.2m | $3.0m | — | |
| Other Operating Expenses | — | — | — | — | ($1.2m) | ($506k) | — | |
| Operating Expenses | $24.9m | $45.5m | $48.7m | $84.7m | $84.1m | $71.1m | $38.5m | |
| Other Operating Income | — | — | $869k | $0 | $1.2m | $506k | — | |
| Loss from operations | ($20.0m) |
($45.2m)
-125.59%
|
($4.0m)
+91.06%
|
($83.9m)
-1976.57%
|
($68.0m)
+19.00%
|
($70.6m)
-3.80%
|
— | |
| Operating Income (Loss) | ($20.0m) |
($45.2m)
-125.59%
|
($4.0m)
+91.06%
|
($83.9m)
-1976.57%
|
($68.0m)
+19.00%
|
($70.6m)
-3.80%
|
($38.5m)
+45.42%
|
|
| Interest Expense, Debt | $3.6m | — | — | — | — | — | $53k | |
| Interest income | $0 | $2k | $3.1m | $2.9m | $2.7m | $2.0m | $1.6m | |
| Net Non Operating Interest Income Expense | — | — | $3.1m | $2.8m | $2.6m | $1.9m | $1.5m | |
| Foreign Currency Transaction Gain (Loss), before Tax | $462k | $325k | $26.4m | ($7.6m) | $2.4m | ($9.6m) | — | |
| Other income | $42k | $332k | $567k | $1.1m | $135k | $16k | — | |
| Other Nonoperating Income (Expense) | $42k | $332k | $567k | $1.1m | $135k | $16k | — | |
| Interest Expense (non-operating) | $3.6m | $2.7m | $19k | $28k | $53k | $51k | $53k | |
| Other Income Expense | — | — | $567k | $1.1m | ($12.1m) | ($4.7m) | ($5.0m) | |
| Total other income, net | $2.2m | ($5.9m) | $4.9m | $7.4m | $6.7m | $3.9m | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | ($50.5m) | ($27.5m) | ($42.5m) | ($42.0m) | |
| Pre-Tax Income | — | ($51.1m) | $850k | ($76.5m) | ($61.2m) | ($66.6m) | ($42.0m) | |
| Loss before income tax | — | ($51.1m) | $850k | ($76.5m) | ($61.2m) | ($66.6m) | — | |
| Tax benefit | ($95k) | $28k | $4.5m | $3.1m | $44k | $175k | — | |
| Income Tax Expense (Benefit) | $95k | ($28k) | ($4.5m) | ($3.1m) | ($44k) | ($175k) | ($167k) | |
| Net loss | ($17.9m) | ($51.1m) | $5.3m | ($73.4m) | ($61.2m) | ($66.5m) | — | |
| Net Income From Continuing And Discontinued Operation | ($17.7m) | ($50.9m) | $5.3m | ($73.3m) | ($61.1m) | ($66.4m) | ($41.8m) | |
| Net Income Continuous Operations | ($17.9m) | ($51.1m) | $5.3m | ($73.4m) | ($61.2m) | ($66.5m) | ($41.8m) | |
| Net loss attributable to Barinthus Biotherapeutics plc shareholders | ($17.7m) | ($50.9m) | $5.3m | ($73.3m) | ($61.1m) | ($66.4m) | — | |
| Net loss attributable to noncontrolling interest | $227k | $247k | $21k | $100k | $109k | $30k | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | ($227k) | ($247k) | ($21k) | ($100k) | ($109k) | ($30k) | ($41.8m) | |
| Earnings Per Share, Basic | ($2.24) | ($1.96) | $0.14 | ($1.91) | ($1.55) | ($1.64) | ($1.02) | |
| Earnings Per Share, Diluted | ($2.24) | ($1.96) | $0.14 | ($1.91) | ($1.55) | ($1.64) | ($1.02) | |
| Weighted Average Number of Shares Outstanding, Basic | 7.9m | 25.9m | 37.2m | 38.4m | 39.3m | 40.5m | 40.8m | |
| Weighted-average ordinary shares outstanding, basic (in shares) | 7.9m | 25.9m | 37.2m | 38.4m | 39.3m | 40.5m | — | |
| Weighted-average ordinary shares outstanding, diluted (in shares) | 7.9m | 25.9m | 38.2m | 38.4m | 39.3m | 40.5m | — | |
| Basic Average Shares | 7.9m | 25.9m | $37.2m | $38.4m | $39.3m | $40.5m | $40.8m | |
| Diluted Average Shares | 7.9m | 25.9m | $38.2m | $38.4m | $39.3m | $40.5m | $40.8m | |
| Weighted Average Number of Shares Outstanding, Diluted | 7.9m | 25.9m | 38.2m | 38.4m | 39.3m | 40.5m | 40.8m | |
| Additional Financial Items | ||||||||
| Goodwill, Impairment Loss | — | — | $0 | $0 | $12.2m | $0 | $4.7m | |
| Impairment of intangible assets | — | — | — | — | $0 | $4.7m | — | |
| Goodwill impairment | — | — | — | $0 | $12.2m | $0 | $4.7m | |
| Other comprehensive gain/(loss) – foreign currency translation adjustments | ($776k) | ($7.2m) | ($25.1m) | $10.2m | ($2.5m) | $10.1m | — | |
| Comprehensive loss | ($18.7m) | ($58.4m) | ($19.8m) | ($63.3m) | ($63.7m) | ($56.3m) | — | |
| Comprehensive loss/(gain) attributable to noncontrolling interest | $227k | $250k | $132k | $94k | $105k | $22k | — | |
| Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders | ($18.5m) | ($58.1m) | ($19.6m) | ($63.2m) | ($63.6m) | ($56.3m) | — | |
| Diluted EPS | ($2.24) | ($1.96) | $0.14 | ($1.91) | ($1.55) | ($1.64) | ($1.02) | |
| Diluted NI Availto Com Stockholders | ($17.7m) | ($50.9m) | $5.3m | ($73.3m) | ($61.1m) | ($66.4m) | ($41.8m) | |
| Impairment Of Capital Assets | — | — | — | $0 | $12.2m | $4.7m | $4.7m | |
| Minority Interests | $227k | $247k | $21k | $100k | $109k | $30k | $40k | |
| Normalized EBITDA | — | — | $5.2m | ($71.1m) | ($43.2m) | ($56.1m) | ($38.4m) | |
| Normalized Income | — | — | $5.3m | ($73.3m) | ($48.9m) | ($61.8m) | ($37.1m) | |
| Other Gand A | $10.5m | $25.1m | $6.4m | $39.8m | $29.7m | $40.8m | — | |
| Reconciled Depreciation | — | — | $4.3m | $5.4m | $5.8m | $5.8m | $3.5m | |
| Selling General And Administration | $10.5m | $25.1m | $6.4m | $39.8m | $29.7m | $40.8m | — | |
| Special Income Charges | — | — | $0 | $0 | ($12.2m) | ($4.7m) | ($4.7m) | |
| Tax Effect Of Unusual Items | — | — | $0 | $0 | ($9k) | ($13k) | ($19k) | |
| Tax Provision | $95k | ($28k) | ($4.5m) | ($3.1m) | ($44k) | ($175k) | ($167k) | |
| Tax Rate For Calcs | — | — | $0 | $0 | $0 | $0 | $0 | |
| Business Combination, Acquisition Related Costs | — | — | — | — | — | $2.8m | — | |
| Operating Expense | — | — | $47.5m | $81.3m | $66.7m | $63.9m | $38.5m | |
| Total Unusual Items | — | — | $0 | $0 | ($12.2m) | ($4.7m) | ($4.7m) | |
| Total Expenses | — | — | $47.5m | $81.3m | $66.7m | $63.9m | $38.5m |